Si-bone, Inc. · NASDAQ:SIBN
Si-bone — Investor Presentation (January 2024)
24 slides from Si-bone's investor presentation, Jan 8, 2024
Slide 1: SI-BONE Corporate Overview January 2024
SI-BONE Corporate Overview January 2024
Slide 2: Forward-looking statements
This presentation contains “ forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as “intends,” “estimates,” “anticipates,” “hop
Slide 3: Identifying Unmet Clinical Needs in the Sacropelvic Space
Identifying Unmet Clinical Needs in the Sacropelvic Space Innovation 3 Differentiated Product Families 77 WW Patents Evidence 2 Randomized Controlled Trials 125+ Peer-reviewed Publications Education 3,600+ WW Surgeons 1 95,000+ Procedures Performed 2 Commercialization 82 Territory Managers 150+ CSS
Slide 4: Large Addressable Markets with Attractive Fundamentals
Large Addressable Markets with Attractive Fundamentals ~470,000 Target U.S. Annual Procedures 1 > $3 Billion Total U.S. Addressable Market 1 280,000 60,000 130,000 SI Joint Dysfunction 2 Pelvic Trauma 5 Adult Deformity 3+ Degenerative Spine 4 Spinopelvic Fixation $2.4 Billion $0.3 Billion $1.0 Billi
Slide 5: Strong Demand Drove Record Revenue in 2023
WW REVENUE ($M) Strong Demand Drove Record Revenue in 2023 5 2023 WW REVENUE ($M) 2023 U.S. REVENUE ($M) $32.7 $33.3 $34.0 1Q23 2Q23 3Q23 4Q23E $30.5 $31.2 $32.3 1Q23 2Q23 3Q23 4Q23E Note: As of January 8, 2024 Note: The fourth quarter and full year 2023 revenue and cash and marketable securities in
Slide 6: Continued Record Surgeon Engagement
Continued Record Surgeon Engagement 6 U.S. ACTIVE SURGEON BASE 925 1,130 4Q22 4Q23 ~22% 12th consecutive quarter of double- digit U.S. active surgeon growth 7th consecutive quarter of 20%+ U.S. procedure volume growth Note: Rounded numbers as of January 8, 2024 Note: The fourth quarter and full year
Slide 7: Entering 2024 With a Strong Balance Sheet
Entering 2024 With a Strong Balance Sheet 7 Note: As of January 8, 2024 Note: The fourth quarter and full year 2023 revenue and cash and marketable securities included in this release are preliminary and prior to the completion of SI-BONE's financial closing procedures and audit procedures by its ex
Slide 8: Pioneering Sacropelvic Solutions
1/5/2024 Pioneering Sacropelvic Solutions 8 >95,000 Procedures >3,600 Surgeons >300M U.S. Covered Lives Note: As of January 8,2024
Slide 9: Major Joints Market
LAST JOINT LARGEST JOINT SI JOINT Major Joints Market 9
Slide 10: A Major Gap in Sacroiliac Joint Therapy
A Major Gap in Sacroiliac Joint Therapy NON-SURGICAL MANAGEMENT SURGERY MEDICATIONS, PHYSICAL THERAPY THERAPEUTIC INJECTIONS RADIO-FREQUENCY ABLATION OPEN SI JOINT FUSION MIS SI JOINT FUSION 10
Slide 11: Diagnostic Algorithm Acceptance and Adoption
11 Diagnostic Algorithm Acceptance and Adoption Source: Petersen, et al. BMC Musculoskeletal Disorders. 2017;18(1):188. DOI 10.1186/s 12891-017-1549-6 PATIENT HISTORY PROVOCATIVE TESTS LOCAL ANESTHETIC INJECTION MEDICARE (MACs) PRIVATE PAYORS Accuracy equals or exceeds other lumbar spine diagnoses
Slide 12: Comprehensive Sacropelvic Solutions Portfolio
Comprehensive Sacropelvic Solutions Portfolio iFuse / iFuse 3D Market Leader in SI Joint Fusion iFuse TORQ Disruptive Technology for Fragility Fractures SI Joint Fusion Pelvic Trauma Adult Deformity iFuse Bedrock Granite Breakthrough Fixation and Fusion Solution Adult Deformity Degenerative Spine iF
Slide 13: Patent Protected Differentiated Platform
Patent Protected Differentiated Platform ▪ 77 issued patents: U.S. (59), OUS (18) ▪ iFuse implant patent until Dec 2025 ▪ Triangular broach instrument patent until Feb 2034 ▪ iFuse-3D implant patents until Sept 2035 3-D TECHNOLOGY Rectilinear profile, longitudinal struts, and struts connecting the l
Slide 14: Proprietary, Differentiated iFuse Technology
Proprietary, Differentiated iFuse Technology® Rotation 6x resistance (vs. 12mm Rialto screw)1 Strength 3x strength (vs. stand 8.0mm cannulated screw)2 Safety Low complication rate3,4 Revision 3.5% (4-year)5 Clinical Evidence 125+ publications (2 RCTs)6 Surface Porous 1. SI-BONE Technical
Slide 15: Robust Clinical Evidence
Robust Clinical Evidence • 125+ peer-reviewed published papers • 5-year long-term, prospective data • Two Level 1 randomized studies 15 www.si-bone.com/results
Slide 16: SALLY Prospective Clinical Trial: iFuse-3D 2-year Outcomes
16 SALLY Prospective Clinical Trial: iFuse-3D 2-year Outcomes1 Rapid, marked and durable improvements in pain, patient function and quality of life VAS Pain Reduction ODI Disability Improvement Decreased Opioid Use 57-point improvement (MCID 20 points) 25-point improvement (MCID 15 points) 59% at ba
Slide 17: iFuse TORQ: Cutting-Edge Pelvic Fixation and Fusion
17 iFuse TORQ®: Cutting-Edge Pelvic Fixation and Fusion Large, Adjacent Market 1 FuSIon 3D Surface for Osseointegration Differentiated Technology TORQLock Threads2 10x rotational resistance on insertion vs. trauma screws Competitive Advantages ~$350 million Pelvic Trauma opportunity 1. Based on inte
Slide 18: iFuse Bedrock Granite: Optimized for Fusion and Fixation
18 iFuse Bedrock Granite®: Optimized for Fusion and Fixation Large, Adjacent Market ~$1 billion Adult Spinal Deformity and Degenerative Spine pelvic fixation opportunity1 Competitive Advantages Breakthrough Device Designation by the FDA Expanded Rod Combability allows use with wide variety of pedicl
Slide 19: Long-Term Business Drivers
Expand Access to Solutions Accelerate market expansion Increase Surgeon Engagement Drive surgeon penetration and adoption Expand Addressable Markets Build differentiated portfolio Long-Term Business Drivers Platform Set-up to Deliver Strong Revenue Growth and Operating Leverage 19 1. Adjusted EBITDA
Slide 20: Differentiated Portfolio Complemented By Strong Fundamentals
20 Differentiated Portfolio Complemented By Strong Fundamentals Robust Data Reimbursement Advantage Proven Execution Track Record Large, Underpenetrated Markets ▪ 125+ published papers ▪ 2 randomized controlled trials ▪ >300 million U.S. covered lives ▪ NTAP for iFuse Bedrock Granite ▪ ~30% worldwid
Slide 21: Pioneering Sacropelvic Solutions
1/5/2024 Pioneering Sacropelvic Solutions 21 >95,000 Procedures >3,600 Surgeons >300M U.S. Covered Lives Note: As of January 8,2024
Slide 22: Disclosure
Disclosure The iFuse Bedrock Granite® Implant System is intended for sacroiliac joint fusion for the following conditions: • Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregna
Slide 23: Disclosure
Disclosure The iFuse Implant System® is intended for sacroiliac fusion for the following conditions: • Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartu
Slide 24: SI-BONE Sacropelvic Solutions
iFuse 3D. SI-BONE. Sacropelvic Solutions™ SI Joint Dysfunction Pelvic Trauma Spinopelvie Fixation